Swiss pharma suspected of delaying generic competition

Summary:
Switzerland is home to a thriving pharmaceutical industry. (Keystone) - Click to enlarge The United States Food and Drug Administration (FDA) published Thursday a list of pharmaceutical companies that include Basel-based Novartis and Roche, all of which are suspected of hindering the development of generic versions of their own medicines. Over 150 complaints were filed. The FDA slammed the development of techniques designed to complicate or even prevent developers of generic drugs from accessing sufficient quantities of original preparations to be able to do comparative studies essential to any application for approval. The authority said it has received more than 150 complaints over the alleged misuse of FDA

Topics:
Swissinfo considers the following as important: 3) Swiss Markets and News, Business, Featured, newsletter

This could be interesting, too:

Alex J. Pollock writes How Does the Federal Reserve Fit into Our Constitutional Order?

Adnan Al-Abbar writes What Can Carl Menger Teach Us about Falafel Sandwiches?

James Bovard writes Biden Perpetuates Washington’s Idiotic Steel Trade Policies

Alex J. Pollock writes The Federal Reserve’s Capital Has Now Plummeted to Negative 1 Billion